Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial by Vilar Gomez, Eduardo et al.
Viusid, a nutritional supplement,
increases survival and reduces disease
progression in HCV-related
decompensated cirrhosis: a randomised
and controlled trial
Eduardo Vilar Gomez,
1 Yoan Sanchez Rodriguez,
2 Ana Torres Gonzalez,
2
Luis Calzadilla Bertot,
2 Enrique Arus Soler,
1 Yadina Martinez Perez,
3
Ali Yasells Garcia,
3 Maria del Rosario Abreu Vazquez
4
ABSTRACT
Objectives: Viusid is a nutritional supplement with
recognised antioxidant and immunomodulatory
properties which could have beneﬁcial effects on
cirrhosis-related clinical outcomes such as survival,
disease progression and development of hepatocellular
carcinoma (HCC). This study evaluated the efﬁcacy
and safety of viusid in patients with HCV-related
decompensated cirrhosis.
Design: A randomised double-blind and placebo-
controlled study was conducted in a tertiary care
academic centre (National Institute of
Gastroenterology, Havana, Cuba). The authors
randomly assigned 100 patients with HCV-related
decompensated cirrhosis to receive viusid (three oral
sachets daily, n¼50) or placebo (n¼50) during
96 weeks. The primary outcome of the study was
overall survival at 96 weeks, and the secondary
outcomes included time to disease progression, time
to HCC diagnosis, time to worsening of the prognostic
scoring systems ChildePugh and Model for End-Stage
Liver Disease, and time to a new occurrence or relapse
for each one of the main clinical complications
secondary to portal hypertension at 96 weeks.
Results: Viusid led to a signiﬁcant improvement in
overall survival (90%) versus placebo (74%) (HR 0.27,
95% CI 0.08 to 0.92; p¼0.036). A similar improvement
in disease progression was seen in viusid-treated
patients (28%), compared with placebo-treated
patients (48%) (HR 0.47, 95% CI 0.22 to 0.89;
p¼0.044). However, the beneﬁcial effects of viusid
were wholly observed among patients with ChildePugh
classes B or C, but not among patients with
ChildePugh class A. The cumulative incidence of HCC
was signiﬁcantly reduced in patients treated with viusid
(2%) as compared with placebo (12%) (HR 0.15, 95%
CI 0.019 to 0.90; p¼0.046). Viusid was well tolerated.
Conclusions: The results indicate that treatment with
viusid leads to a notable improvement in overall
clinical outcomes such as survival, disease
progression and development of HCC in patients with
HCV-related decompensated cirrhosis.
Trial registration number: http://ClinicalTrials.gov
(NCT00502086).
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ARTICLE SUMMARY
Article focus
- Hepatitis C virus (HCV)-related decompensated
cirrhotic patients have a poor therapeutic
response and reduced tolerance to the current
standard of care therapy.
- Therapeutic goals in these patients should be
directed towards reducing liver-related morbidity
and mortality, and the need for liver trans-
plantation.
- Viusid is a nutritional supplement with recog-
nised antioxidant and immunomodulatory prop-
erties that could modulate the histological
pattern of CHC, especially inﬂammation and
ﬁbrosis, in an attempt to halt disease progression
and consequently improve liver function and
liver-related morbidity and mortality, and prevent
development of hepatocellular carcinoma (HCC).
Key messages
- The administration of viusid to HCV-related
decompensated cirrhotic patients induced
a signiﬁcant improvement of overall survival,
a signiﬁcant reduction in the disease progression
and development of HCC.
- The beneﬁt of viusid was also seen in the
secondary end point of worsening of the
prognostic scores such as Model for End-Stage
Liver Disease and ChildePugh scores.
- Theviusideffectsonsurvivalanddiseaseprogres-
sion were selective for patients with advanced
stage of liver disease (ChildePugh B or C).
- Viusid was well tolerated, and only minor
transient adverse events such as nausea and
diarrhoea were reported.
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Open Access ResearchINTRODUCTION
Chronic hepatitis C virus (HCV) infection is a leading
cause of end-stage liver disease and hepatocellular
carcinoma (HCC) worldwide
1 and the most common
indication for orthotopic liver transplantation in the
western world.
2 Once HCV cirrhosis has developed, the
risk of clinical decompensation is about 5% per year,
3e5
and the risk of mortality is considerably high with
a survival rate of 50% at 5 years.
67Cumulative data of
patients with compensated cirrhosis indicate that the
5-year risk of decompensation is estimated to be
15e28%, and the annual risk of developing HCC is
1.4e6.7%.
348Liver-related mortality increases consid-
erably as soon as decompensation is established, and
then liver transplantation is the only successful thera-
peutic option. Unfortunately, once the liver is grafted,
disease recurrence is universal. The recurrence of the
infection leads to cirrhosis in approximately 25% of the
transplant recipients within 5e10 years after trans-
plantation. The cumulative probability of decompensa-
tion 1 year after cirrhosis is in the order of 30%, and the
1-year survival is 46%.
9
HCV-related cirrhotic patients have a poor therapeutic
response and reduced tolerance to the current standard
of care (SOC) therapy.
10e15 Peginterferon (PEG-IFN)
plus ribavirin (RBV) is the recommended treatment
strategy for patients with compensated cirrhosis.
16
However, the efﬁcacy of antiviral therapy is in this group
signiﬁcantly lower than in non-cirrhotic patients,
achieving the poorest rates of sustained virological
response (SVR, 5e25%) in patients with genotype 1e4.
17
Current evidence indicates that antiviral treatment with
PEG-IFN alone or in combination with RBV reduces the
rate of clinical decompensation, improves liver-related
survival and decreases the development of HCC, but
only in those patients who achieved SVR.
18e20 However,
this beneﬁt should be balanced with severe side effects
that lead to therapy discontinuation and derangement
of liver function in a high proportion of patients with
ChildePugh (CP) class BeC cirrhosis.
Thus, an effective treatment is needed immediately in
cirrhotic patients who have failed to achieve SVR or with
advanced disease to avoid further deterioration and
death.
Several studies have demonstrated an important asso-
ciation between increased levels of products related to
oxidative stress and advanced stages of the disease.
21 22
Likewise, cytokine dysregulation is thought to play
a crucial role in the persistence of viral infection and as
a key mediator in inﬂammatory and ﬁbrogenic processes
in patients with HCV infection.
23 Therefore, the
administration of compounds with antioxidant and
immunomodulatory properties could be a plausible
strategy to halt the natural course of the disease,
particularly in cirrhotic patients with advanced disease.
Viusid (Catalyis laboratory, Madrid, Spain) is a nutri-
tional supplement that contains different molecules
(ascorbic acid, zinc and glycyrrhizic acid) with recog-
nised antioxidant and immunomodulatory properties
(table 1).
24e26 Glycyrrhizin (0.033 g), the most impor-
tant active ingredient of the supplement, is known to
have various immune-modulating, antiviral and biolog-
ical response-modiﬁer activities. It demonstrated
different anti-inﬂammatory properties (increased
production of interleukin 10 (is a potent anti-inﬂam-
matory cytokine which inhibits the syntheses of many
pro-inﬂammatory proteins)), an anti-apoptotic effect,
hepatocyte proliferation and stabilisation of hepatic
cellular membranes.
27e30
Encouraging effects of viusid on liver histology have
been reported in patients with non-alcoholic fatty liver
disease and chronic hepatitis C.
31 32 The authors
reported that the addition of viusid to the conventional
interferon/ribavirin therapy was associated with signiﬁ-
cant histological and biochemical improvements, espe-
cially in patients without a sustained virological
response. In another study, the same authors showed
that the administration of viusid combined with a life-
style modiﬁcation based on a hypocaloric diet and
exercise during 6 months was associated with marked
histological improvements in steatosis, lobular inﬂam-
mation, ballooning and NAFLD activity score in patients
with non-alcoholic fatty liver disease. No signiﬁcant
clinical and laboratory adverse events (AEs) have been
reported with the use of viusid in previous trials.
Recent data suggest that viusid improves oxidative
stress through reduction of lipid peroxidation products
and has an immunomodulatory effect on cytokine
Table 1 Ingredients of viusid
Malic acid 0.666 g
Glycyrrhizic acid 0.033 g
Glucosamine 0.666 g
Arginine 0.666 g
Glycine 0.333 g
Calcium pantothenate 0.002 g
Ascorbic acid 0.020 g
Folic acid 66 mg
Cyanocobalamine 0.3 mg
Zinc sulfate 0.005 g
Pyridoxal 0.6 mg
ARTICLE SUMMARY
Strengths and limitations of this study
- The main strength of this study was to demonstrate that viusid
improves overall clinical outcomes (survival, HCC and disease
progression) in cirrhotic patients who have failed to achieve
sustained virological response with standard of care, and these
beneﬁts appear to be more prominent in patients with poorer
liver function (ChildePugh B or C).
- The study was designed with a small sample size.
- Further multicentre and large-scale studies are needed to
corroborate the impact of viusid on the clinical outcomes in
patients with HCV-related decompensated cirrhosis.
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Viusid and HCV-Related Decompensated Cirrhosissecretion via increased production of IFN-g and inter-
leukin (IL)-10, decreased production of IL-1a and
stabilised tumour necrosis factor-a secretion in patients
with HCV who have failed previous antiviral treatment.
33
All of these effects could modulate the histological
pattern of CHC, especially inﬂammation and ﬁbrosis in
an attempt to halt disease progression and consequently
improve liver function and liver-related morbidity and
mortality, and prevent the development of HCC.
Thus, a randomised double-blind and placebo-
controlled study was conducted to evaluate whether
viusid may have a beneﬁcial effect on survival, time to
disease progression and time to diagnosis of HCC in
HCV-related cirrhotic patients with decompensated
disease.
MATERIALS AND METHODS
Participants
We recruited 100 patients with HCV liver-related
cirrhosis at a tertiary care academic centre (National
Institute of Gastroenterology, Havana, Cuba) between
May 2005 and June 2007, and who fulﬁlled the following
inclusion criteria: male and female patients of
18e70 years of age, clinical or histological diagnosis of
cirrhosis, naı ¨ve patients or non-responders to previous
treatment with PEG-IFN plus RBV with decompensated
cirrhosis, deﬁned as a ChildePugh score $7 or clinical
evidence or history of ascites, encephalopathy, upper-
gastrointestinal bleeding and/or impaired hepatic
synthetic function, who had contraindicated the antiviral
treatment, absence of active alcoholism (alcohol absti-
nence was monitored at each clinic visit in the course of
patient interview) and ability to provide informed
consent. Patients were excluded if they had presence of
other causes of liver disease, uncontrollable clinical or
biochemical complications related to severe liver failure
(hepatic encephalopathy, hepatorenal syndrome,
gastrointestinal bleeding, serum total bilirubin
>85 mmol/l (5 mg/dl), international normalised ratio
>2.5), serum creatinine >180 mmol/l (2 mg/dl), posi-
tive screening for viral hepatitis A and B and HIV, preg-
nancy or lactation, concomitant disease with reduced life
expectancy, severe psychiatric conditions, drug depen-
dence, and if they had presence of other causes of liver
diseases at entry into the study on the basis of ultraso-
nography and a-fetoprotein levels higher than 200 ng/l.
Ethics
The study was conducted in compliance with the
Declaration of Helsinki and approved by the ethics
committee and the institutional review board of the
National Institute of Gastroenterology. All patients
provided written informed consent for participation.
Interventions
After initial evaluation, all patients who met the eligi-
bility criteria were consecutively enrolled in the study.
They were randomly assigned to receive: viusid (three
oral sachets daily, n¼50) or placebo (three oral sachets
daily, n¼50) for 96 weeks.
Randomisation was conducted by blocks of four (block
randomisation) and performed by a health worker
experienced in randomisation techniques and not
involved in the evaluation or treatment of the partici-
pants. The physicians, study coordinators and patients
did not have access to the randomisation scheme.
The researchers, study coordinators and patients were
blinded as to the treatment administered. When the
patients were allocated, they brought their entry code to
the pharmacy which was provided with the randomised
list.Thecodewas revealedtotheresearchersattheendof
the study protocol. Catalysis, Madrid, Spain provided the
viusid and placebo sachets. There was no difference in
appearance,smellandﬂavourbetweenviusidandplacebo.
Treatment started 4 weeks after the clinical evidence of
decompensation had been treated and controlled with
appropriate therapy.
Clinical and laboratory assessment
All patients were closely monitored for clinical,
biochemical and haematological assessment at baseline,
weekly for the ﬁrst 8 weeks, and every 8 weeks thereafter
until the end of the study.
Clinical assessment included physical examination
along with compliance with the study medication (veri-
ﬁed through sachet count). Biochemical and haemato-
logical evaluations included complete blood count, liver
tests, glucose, coagulation and renal-function tests.
We deﬁned overweight as a BMI of 25 to 30 kg/m
2 and
deﬁned obesity as a BMI of >30 kg/m
2. Patient’s data
with diagnosis of diabetes mellitus at baseline, elevated
fasting glucose levels (>6.1 mmol/l), a positive glucose
tolerance test and antidiabetic medication used were
recorded.
Liver ultrasonography and serum a-fetoprotein deter-
minations were carried out at baseline and every
24 weeks during the study to screen for HCC.
An upper-digestive endoscopy was performed before
admission.
The HCV-RNA level was quantiﬁed by PCR assay
(Amplicor Monitor HCV v.2.0; Roche Molecular System;
lower limit of detection, 600 IU/ml). HCV genotyping
was performed by reverse hybridisation (Inno-LiPA
HCV; Innogenetics, Ghent, Belgium).
Deﬁnition of outcomes
The terminology to deﬁne outcomes in this study was
slightly modiﬁed as compared with the original protocol
because it is more precise and less subjective to assess
time-dependent clinical complications in cirrhotic
patients. Additionally, primary and secondary outcomes
are in accordance with standardised terminology used in
the majority of the trials evaluating the impact of treat-
ments on patients with HCV-related cirrhosis.
The primary outcome of the study was overall survival
(OS), which was measured from the date of random-
isation until the date of death (related to liver disease).
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were censored at the time of death or discontinuation,
and patients undergoing liver transplantation were
censored at the transplant date.
Secondary outcomes included the time to disease
progression, time to diagnosis of HCC, time to wors-
ening of the prognostic scoring systems ChildePugh and
Model for End-Stage Liver Disease (MELD), time to
a new occurrence or relapse for each of the main clinical
complications secondary to portal hypertension and
safety.
The time to disease progression was reﬂected as the
time between random assignment and disease progres-
sion, deﬁned as the incidence of liver-related death, the
development of HCC or the ﬁrst occurrence or relapse
(only for those patients with a previous history of clinical
decompensation) of at least one of the following clinical
conditions: ascites, hepatic encephalopathy, sponta-
neous bacterial peritonitis, hepatorenal syndrome or
upper-gastrointestinal bleeding secondary to portal
hypertension.
The time to diagnosis of HCC was calculated from the
date of randomisation to the date of occurrence of HCC.
Diagnosis of HCC was implemented using currently
accepted diagnostic criteria for HCC.
34e36
The time to worsening of the prognostic scores was
deﬁned as the time from randomisation to worsening of
the ChildePugh score in at least two points and the
MELD score in at least four points on the basis of
independent clinical evaluation on two consecutive
study visits. The ChildePugh and MELD scores are
measures of the severity of liver disease, with higher
numbers indicating greater decompensation.
The time to a new occurrence or relapse for each of
the main clinical complications secondary to portal
hypertension was deﬁned from the date of random-
isation to the date of a new occurrence or relapse (only
for those patients with a previous history of clinical
complications) of the following clinical conditions:
ascites, hepatic encephalopathy, upper-gastrointestinal
bleeding, hepatorenal syndrome and spontaneous
bacterial peritonitis.
The evidence for each end point was veriﬁed and
conﬁrmed by two blinded independent hepatologists.
Safety was assessed by dynamic reports of AEs, clinical
laboratory test (haematological and biochemical anal-
ysis), physical examination and measurement of vital
signs. The presence of sepsis and hospitalisation were
included in the safety reports. Episodes of sepsis were
recorded,andtheywerediagnosedandtreatedaccording
to recommended guidelines. Sepsis was graded as severe
if requiring hospitalisation or treatment discontinuation.
Statistical methods
The baseline characteristics were summarised in
percentage for categorical variables and as mean6SD
for continuous variables. The c
2 test was applied to
categorical variables. The two-sample t test was used to
compare means, and the ManneWhitney U test if they
were not normally distributed. Outcome measurements
included all patients who were randomised and received
at least one dose of study medication (intention-to-treat
analysis). The safety analysis included all treated patients
who had at least one safety evaluation after baseline.
Both primary and secondary outcomes were analysed
by the KaplaneMeier method, and differences were
compared using Cox proportional hazard models
adjusted by sex and age, baseline CP and MELD scores,
previous history of clinical decompensation, and current
use of diuretics and propranolol.
We deﬁned OS time at 96 weeks as a primary end point
to compute sample size. The study was designed to have
a statistical power of 80% to detect an absolute differ-
ence of 25% in the survival rates at 96 weeks (95% in the
experimental group vs 70% in the control group).
Considering a type I error of 0.05 and a type II error of
0.20, 43 patients per arm were needed to reach statistical
signiﬁcance. After considering patient loss as a result of
dropout, we set the target number of patients at 50 per
arm, or 100 in total.
All CIs, signiﬁcance tests and resulting p values were
two-sided, with an a level of 0.05.
Statistical analyses were performed using STATA
software, release 11.
The study was designed by Catalysis Laboratory in
conjunction with the principal investigator. The data
were collected and analysed by the investigators. All
authors had access to the data.
RESULTS
Patients
Between May 2005 and June 2007, 124 patients were
screened. One hundred of these patients met the eligi-
bility criteria and were randomly assigned to the viusid
(n¼50) and the placebo arms (n¼50). These patients
were all included in the intention-to-treat analysis.
Twenty-four patients were excluded from the study
during the screening period because they did not meet
the inclusion criteria, met one or more of the exclusion
criteria or withdrew their consent. The ﬂow of the
participants through the trial is presented in ﬁgure 1.
None of the patients received co-interventions during
the trial that could have affected the outcomes. One
death secondary to myocardial infarction occurred in
each group of treatment during the study. Four of the
seven patients with HCC were not discontinued and
completed the study because diagnosis was made only at
the end of the treatment.
Demographic and baseline disease characteristics of
the ITT population were generally well balanced
between treatment arms (table 2). The patients’ mean
age was 57.5 years, and 60% were women. All patients
had genotype 1 infection. The mean CP and MELD
scores at baseline were 6.32 and 12.94, respectively.
All patients with a previous history of hepatic decom-
pensation were controlled and treated with appropriate
therapy before trial admission.
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Viusid and HCV-Related Decompensated CirrhosisAt study entry, none of the patients had any evidence
of HCC, ascites, hepatic encephalopathy, renal failure,
upper-gastrointestinal bleeding or spontaneous bacterial
peritonitis.
Efﬁcacy (primary end point)
OS at 96 weeks was signiﬁcantly higher in the patients
assigned to the nutritional supplement (90% with a 95%
CI 75 to 95) as compared with the patients assigned to
placebo (74% with a 95% CI 56 to 83; HR 0.27; 95% CI
0.08 to 0.92; p¼0.036; table 3). However, the beneﬁcial
effects of viusid on survival appear to be selective for
patients with poor hepatic reserve (ChildePugh B or C)
(ﬁgure 2A). Survival in patients with CP classes B or C
was signiﬁcantly higher in the experimental group than
in the placebo group (80% vs 48%; HR in the viusid
group, 0.36; 95% CI 0.10 to 0.91; p¼0.041).
Efﬁcacy (secondary end points)
The KaplaneMeier estimates of the proportion of
patients with disease progression at 96 weeks (table 3)
were 28% (95% CI 19 to 45) in the experimental group
and 48% (95% CI 38 to 66) in the control group. The
HR for the viusid arm was 0.47 (95% CI 0.22 to 0.89;
p¼0.044). Nevertheless, this effect was seen among
patients classiﬁed as ChildePugh B or C, but not among
patients with CP classes A (ﬁgure 2B). Among patients
with CP scores B or C, the disease progression rates were
lower in patients treated with the experimental inter-
vention (47%) and were progressively higher in patients
assigned to placebo arm (80%) (HR in the viusid arm,
0.51; 95% CI 0.23 to 0.96; p¼0.047; ﬁgure 2B).
The cumulative incidence of HCC at 96 weeks was 2%
(95% CI 0.3 to 15) in the active product-treated patients
and 12% (95% CI 6 to 33) in the placebo group, with
a HR for the group assigned to active product of 0.15
(95% CI 0.019 to 0.90; p¼0.046) (table 3). All patients
with HCC were diagnosed during the second year
after randomisation. Two of the seven patients with HCC
were eligible for liver transplantation, and three had
transarterial chemoembolisation.
An increase in the CP score (ﬁgure 3A) occurred in
seven patients (14%; 95% CI 8 to 32) allocated to the
nutritional supplement group as compared with 19
patients (38%; 95% CI 30 to 59) allocated to the placebo
group. The HR for the viusid arm was 0.34 (95% CI 0.14
to 0.81; p¼0.015). Likewise, a signiﬁcant worsening in
the MELD score (ﬁgure 3B) was observed in 15 indi-
viduals (30%; 95% CI 21 to 49) assigned to placebo as
compared with six individuals (12%; 95% CI 6 to 26)
assigned to nutritional supplement, with an HR for the
viusid group of 0.39 (95% CI 0.15 to 0.92, p¼0.042).
The cumulative incidence of ascites at 96 weeks was
signiﬁcantly higher in the patients assigned to placebo
(32%; 95% CI 14 to 39) than in the patients assigned to
viusid (14%, 95% CI 7 to 28). The HR for the viusid arm
was 0.32 (95% CI 0.11 to 0.90; p¼0.031), but the
differences were not statistically signiﬁcant for hepatic
encephalopathy, upper-gastrointestinal bleeding, and
spontaneous bacterial peritonitis. Type 2 hepatorenal
syndrome was reported in one patient of each group of
treatment. The primary and secondary outcome
measures are summarised in table 3.
Safety
Cramps (33%), asthenia (32%), sepsis (27%), predomi-
nantly bacterial infections and muscle pain (24%) were
the most frequent AEs. The main causes of sepsis were
urinary infection (11%), SBP (6%), pneumonia (5%)
and lymphangitis (3%). None of the patients had
infections related to leucopenia or neutropenia.
A smaller proportion of patients treated with the
nutritional product than treated with placebo had
fatigue (experimental group, 10%; placebo, 26%;
p¼0.04), cramps (experimental group, 22%; placebo,
44%; p¼0.02) and sepsis (experimental group, 14%;
placebo, 40%; p<0.01), respectively.
A high percentage of patients (24%) were hospitalised
during the study secondary to episodes of hepatic
decompensation or severe sepsis; however, there was no
difference between the treatment groups. A summary of
AEs is given in table 4. There were no signiﬁcant labo-
ratory abnormalities in the two study groups. Neither was
there any incidence of viusid discontinuation or dose
modiﬁcation secondary to AEs.
DISCUSSION
HCV-related cirrhotic patients represent an important
population with increased morbidity and mortalities.
Unfortunately, current antiviral therapy, especially for
patients with decompensated disease, is generally limited
by side effects, and early discontinuation is common.
Figure 1 Flow of patients through the study. *Four patients
with hepatocellular carcinoma (HCC) were not discontinued
because diagnosis was made at the end of the treatment.
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therapeutic option for these patients. Recent studies
have demonstrated encouraging SVR rates and, conse-
quently, clinical outcome improvements (OS, HCC and
hepatic decompensation) in decompensated cirrhotic
patients, but this was only achieved in a minority of
patients (SVR, 5e25%) infected with genotype 1e4.
17
Therefore, there is a critical need to explore new
therapeutic options for patients with HCV-related end-
stage liver disease who are never listed for liver trans-
plant and could receive a beneﬁcial impact on their
clinical outcomes.
The study was designed to evaluate the efﬁcacy and
safety of viusid in a particular population of older
cirrhotic patients who had a previous history or current
evidence of clinical hepatic decompensation and
Table 2 Baseline characteristics
Variable Viusid (n[50) Placebo (n[50) p Value*
Age (years) 58.568.9 56.668.4 0.29
Sex, n (%)
Male 22 (44%) 18 (36%) 0.41
Female 28 (56%) 32 (64%)
BMI (kg/m
2) 25.464.6 26.764.5 0.16
BMI >25 (kg/m
2), n (%) 28 (56%) 31 (62%) 0.54
Hepatitis C virus RNA >600000 IU/ml 42 (84%) 38 (76%) 0.45
Genotype 1, n (%) 50 (100%) 50 (100%) 1.0
Clinical scores
ChildePugh Class A 32 (64%) 29 (58%)
ChildePugh Class B 15 (30%) 15 (30%) 0.56
ChildePugh Class C 3 (6%) 6 (12%)
Model for End-Stage Liver Disease 12.563.7 13.364.7 0.46
History of diabetes or fasting
glucose $7 (mmol/l), n (%)
17 (34) 21 (42) 0.41
Previous history of clinical
decompensation, n (%)y
Ascites 22 (44) 14 (32) 0.10
Upper-gastrointestinal bleeding 9 (18) 5 (10) 0.25
Spontaneous bacterial peritonitis 2 (4) 2 (4) 1.00
Hepatic encephalopathy 4 (8) 3 (6) 0.69
Evidence of esophageal varices 23 (46) 18 (36) 0.31
Current propranolol use, n (%) 13 (26) 10 (20) 0.65
Mean doses 70617.7 80637.7 0.37
Current spironolactone use, n (%) 21 (42) 12 (24) 0.09
Mean doses 84.5639.1 111640 0.14
Current furosemide use, n (%) 4 (8) 5 (10) 1.00
Mean doses 40610 64622 0.19
Alanine aminotransferase (U/l) 92.2676.6 82.7649.5 0.86
Aspartate aminotransferase (U/l) 105680.2 94.1656.6 0.72
Fasting plasma glucose (mmol/l) 4.961.2 5.161.3 0.70
Alkaline phosphatase (mmol/l) 290.46108 281678.8 0.96
Creatinine (mmol/l) 160.3 160.3 0.88
Haemoglobin (g/l) 125.8613.8 129.5617.6 0.32
Cholesterol (mmol/l) 3.8560.9 3.8561 0.50
Total bilirubin (mmol/l) 24.3617.6 23.9617.7 0.98
Albumin (g/l) 38.964.3 38.964.3 0.52
Partial thromboplastin time (s) 38.469.7 39.3612.3 0.73
Prothrombin time (s) 4.762.5 5.563.7 0.38
International normalized ratio 1.4960.3 1.5860.4 0.38
White blood cells (310
3/ml) 6.161.9 5.961.7 0.70
Platelets (310
3/ml) 133.7657.9 130.6665.7 0.48
Platelets <100310
3/ml 20 (40) 24 (48) 0.42
a-Fetoprotein (ng/ml) 11616.9 10612.7 0.25
Pluseminus values are means6SD. For all laboratory measures and for continuous demographics: p value ManneWhitney U test. Proportions:
percentage, p value c
2. The ChildePugh and Model for End-Stage Liver Disease scores are measures of the severity of liver disease.
Prothrombin time (s): value is expressed in seconds upper the utilised control. Partial thromboplastin time (s): value in seconds. To convert
mmol/l of bilirubin to mg/dl, multiply by 0.0585. To convert mmol/l of creatinine to mg/dl, multiply by 0.01131.
*p Values are for the comparison between viusid and placebo.
yPrevious history of clinical decompensation within 1 year before enrolment.
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Viusid and HCV-Related Decompensated Cirrhosisgenotype 1 infection, and therefore the poorest chance
of achieving SVR and elevated probabilities of adverse
clinical outcome in their next years of follow-up.
In the current study, we demonstrated that adminis-
tration of a nutritional supplement to HCV-related
decompensated cirrhotic patients induced a signiﬁcant
improvement in OS, compared with placebo. Similarly,
a signiﬁcant reduction in the disease progression,
deﬁned as the presence of liver-related death, the
development of HCC or a ﬁrst occurrence or relapse of
at least one of the main portal hypertension-related
clinical complications, was observed in patients treated
with viusid in comparison with those patients treated
with placebo. However, the effect of viusid on survival
and disease progression was irrelevant for patients with
CP classes A, in contrast with those patients with CP
classes B or C. Interestingly, the cumulative incidence of
HCC was notably reduced in those patients assigned to
experimental arm, compared with placebo arm.
However, a stratiﬁed analysis according to ChildePugh
classes was not performed, owing to a small proportion
of patients with presence of HCC, which could generate
a bias in the interpretation of the results.
In the present study, we found increased rates of
mortality, disease progression and cumulative incidence
of HCC in the placebo group than previously reported
rates in a large, prospective and multicentre trial.
37 The
most likely explanation for the disparity between these
rates appears to be related to the difference in the study
design. Our study was designed to include a large
proportion of patients who had a previous history or
current evidence of clinical hepatic decompensation
(poor hepatic reserve), subjects who were excluded from
the Hepatitis C Antiviral Long-term Treatment against
Cirrhosis (HALT-C) Trial.
37 A recent controlled study
has validated the efﬁcacy and safety of IFN-based therapy
for HCV-related decompensated cirrhotic patients.
14
One of the main advantages of the study was to include
a group of untreated patients (controls) with decom-
pensated events who were enrolled to deﬁne survival and
Table 3 Summary of outcome measures
Variable
Viusid (N[50)
Placebo (N[50) HR* (95% CI) p Value No of patients (%)
Primary outcomes, no (%)
Overall survival 45 (90) 37 (74) 0.27 (0.08 to 0.92) 0.036
Secondary outcomes, no (%)
Time to disease progression 14 (28) 24 (48) 0.47 (0.22 to 0.89) 0.044
Time to diagnosis of hepatocellular
carcinomay
1 (2) 6 (12) 0.15 (0.019 to 0.90) 0.046
Worsening of ChildePugh score in
at least two points
7 (14) 19 (38) 0.34 (0.14 to 0.81) 0.015
Worsening of Model for End-Stage Liver
Disease score in at least four points
6 (12) 15 (30) 0.39 (0.15 to 0.92) 0.042
Ascites 7 (14) 16 (32) 0.32 (0.11 to 0.90) 0.031
Hepatic encephalopathy 1 (2) 5 (10) 0.20 (0.10 to 1.7) 0.10
Spontaneous bacterial peritonitis 1 (2) 5 (10) 0.20 (0.13 to 1.7) 0.09
Upper-gastrointestinal bleeding 8 (16) 10 (20) 0.78 (0.31 to 1.99) 0.67
*HRs were computed using the Cox proportional hazard model adjusted for sex and age, baseline ChildePugh and Model for End-Stage Liver
Disease scores, previous history of clinical decompensation, and current use of diuretics and propranolol. CI denotes the CI for the HR.
yAll cases of hepatocellular carcinoma were diagnosed during the second year of treatment.
Figure 2 KaplaneMeier curves
for (A) survival and (B) time to
disease progression according to
ChildePugh (CP) classes (A vs B
or C). Time to disease progression
was deﬁned as the incidence of
liver-related death, the
development of hepatocellular
carcinoma or the ﬁrst occurrence
or relapse (only for those patients
with a previous history of hepatic
decompensation) of at least one of
the following clinical conditions:
ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, hepatorenal syndrome or upper-gastrointestinal bleeding
secondary to portal hypertension. The CP score is a measure of the severity of liver disease. Numbers in parentheses show the
number of events.
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Viusid and HCV-Related Decompensated Cirrhosisprogression disease during 30 months of follow-up. The
results obtained in this study show that this group of
patients have a poor chance to survive (68%) and
increased rates of hepatic decompensation (88%) and
HCC (10%). These results suggest that the natural
history of HCV-related cirrhotic patients is more accel-
erated in patients with a previous history or current
evidence of clinical hepatic decompensation.
Data from the HALT-C study show an increased annual
risk of HCC in patients with a low platelet count and the
presence of esophageal varices. This could be another
reasonable theory to explain the increased risk of HCC
in our study. In the current study, an elevated percentage
of patients (w50%) had evidence of esophageal varices
and/or thrombocytopenia (<100310
3/ml).
38
Finally, an increased prevalence of diabetes was
reported in our study (42% in placebo group and 34%
in viusid group), which has been associated with
the development of HCC and accelerated disease
progression.
39
In the current study, the rate of new occurrence or
relapse of overall clinical outcome secondary to portal
hypertension was statistically reduced in the patients
assigned to viusid in comparison with those allocated to
placebo. The cumulative incidence of ascites was the
only remarkable clinical condition reduced in the
patients treated with viusid as compared with placebo. In
contrast, no differences were observed between the
treatment groups for hepatic encephalopathy, sponta-
neous bacterial peritonitis, hepatorenal syndrome and
upper-gastrointestinal bleeding.
The beneﬁt of viusid was also seen in the secondary
end point of worsening of the prognostic scores. A
signiﬁcant increase in the CP and MELD scores was
observed in the placebo-treated patients compared with
the experimental group.
During the viusid therapy, the risk of bacterial infec-
tions decreased independently from neutropenia, which
could suggest an improvement in the qualitative neutro-
phil function, but this effect should be additionally
studied.
Viusid was well tolerated, and only minor transient AEs
such as nausea and diarrhoea were reported.
The mechanisms responsible for the beneﬁcial effects
of viusid on the clinical outcomes such as survival,
development of HCC and disease progression have not
yet been fully studied. However, there are several reasons
to understand why its administration might improve
overall clinical end points.
A recent trial has suggested that viusid therapy
combined with SOC in patients with chronic hepatitis C
may reduce inﬂammation and ﬁbrosis, irrespective of
virological response.
32 Another recently published study
has reported a dual role to explain possible mechanisms
Table 4 Incidence of adverse events*
Variable
Viusid (n[50) Placebo (n[50)
p Valuey No (%) No (%)
Asthenia 12 (24) 20 (40) 0.08
Fatigue or malaise 5 (10) 13 (26) 0.04
Muscle pain 8 (16) 16 (32) 0.06
Anorexia 5 (10) 9 (18) 0.24
Cramps 11 (22) 22 (44) 0.02
Discomfort on the right upper quadrant 7 (14) 13 (26) 0.13
Gingival bleeding 5 (10) 10 (20) 0.16
Epistaxis 5 (10) 10 (20) 0.16
Nausea 5 (10) 1 (2) 0.12
Diarrhoea 5 (5) 1 (2) 0.12
Sepsis 7 (14) 20 (40) <0.01
Hospitalisation 9 (18) 15 (30) 0.24
*The adverse events listed are those recorded in at least 5% of the patients in either study group.
yp Values were calculated on the basis of the two-sided c
2.
Figure 3 KaplaneMeier
estimates of the time to worsening
of the (A) ChildePugh (CP) and
(B) Model for End-Stage Liver
Disease (MELD) scores during the
treatment. Numbers in
parentheses show the number of
events. The MELD and CP scores
are measures of the severity of
liver disease.
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33 The authors
found that MDA and 4-hydroxyalkenal levels were
signiﬁcantly reduced in patients treated with viusid,
indicating an important effect on lipid peroxidation
products. Furthermore, viusid provided immunomodu-
latory effects on cytokine secretion via increased
production of anti-inﬂammatory cytokines (IL-10) and
decreased or stabilised production of pro-inﬂammatory
cytokines (IL-1a and tumour necrosis factor-a). Current
studies are focusing on the biological effects of viusid on
hepatic stellate cell apoptosis as a critical step to clarify
the potential mechanism of viusid in liver ﬁbrogenesis.
On the other hand, it would be important to evaluate
whether the viusid effects on the clinical outcomes are
directly related to the signiﬁcant reduction in portal
pressure in cirrhotic patients. Further studies should be
addressed to answer this concern.
Recently, the HALT-C study was designed to determine
whether low-dose peginterferon a 2a maintenance
therapy over 3.5 years could reduce hepatic decompen-
sation, HCC and mortality in patients with advanced
ﬁbrosis or cirrhosis who failed to achieve SVR with
SOC.
37 Unfortunately, no overall reduction in any of
these clinical end points was achieved. Like the HALT-C
study, two other studies (COPILOT and EPIC) failed to
demonstrate any overall beneﬁt on clinical outcomes in
HCV-related cirrhotic patients.
40 41 A recent analysis of
the HALT-C trial has demonstrated that beneﬁts on
clinical outcomes could only be reached in patients with
profound viral suppression obtained with full-dose
peginterferon and ribavirin.
19
The main strength of this study was to demonstrate
that viusid improves overall clinical outcomes (survival,
HCC, and disease progression) in cirrhotic patients who
have failed to achieve SVR with SOC, and these beneﬁts
appear not to be associated with viral suppression rates.
32
Our study was designed with a small sample size.
Therefore, further multicentre and large-scale studies
are needed to corroborate the impact of viusid on the
clinical outcomes in patients with HCV-related decom-
pensated cirrhosis.
In conclusion, the study supports the use of viusid in
patients with HCV-related decompensated cirrhosis who
have failed to achieve SVR, with full-dose peginterferon
and ribavirin in an attempt to prevent disease progres-
sion and improve OS. However, additional studies are
required to conﬁrm the long-term effect of viusid in
patients with poorer liver function (ChildePugh B or C).
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